News One of J&J's blockbuster depression hopes has flamed out Johnson & Johnson has halted the development of aticaprant as a treatment for major depressive disorder, blowing a hole in its late-stage pipeline.
News J&J shares data on would-be blockbuster antidepressant Johnson & Johnson’s seltorexant is one of two new therapies that the company reckons could become blockbuster treatments for depression, and data from a phase 3 trial
News FDA finally okays Novavax's COVID-19 jab, with restrictions The FDA has granted full approval to Novavax's COVID-19 vaccine after a delay, but has limited its use.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.